Korean Circ J.  2010 Feb;40(2):81-85. 10.4070/kcj.2010.40.2.81.

Effectiveness of Medium-Dose Intravenous Immunoglobulin (1 g/kg) in the Treatment of Kawasaki Disease

• Yeo JS
• Choi JW

• KMID: 2297943
• DOI: http://doi.org/10.4070/kcj.2010.40.2.81

Abstract

BACKGROUND AND OBJECTIVES
High-dose intravenous immunoglobulin (IVIG) (2 g/kg) is usually given in the treatment of Kawasaki disease (KD). According to the authors' experience, however, medium-dose immunoglobulin (1 g/kg) was also effective in the majority of patients. We performed a retrospective clinical study to validate effectiveness of the medium-dose regimen in treatment of KD.
SUBJECTS AND METHODS
A total of 274 patients with KD who were treated with medium-dose immunoglobulin at Bundang Jesaeng General Hospital from July 1998 to October 2007 were enrolled.
RESULTS
Medium-dose immunoglobulin was given once in 220 patients (group A; 80.3%) and twice or more in 54 patients (group B; 19.7%). Age and gender distributions, duration of fever before treatment, hemoglobin concentrations, and white blood cell and platelet counts did not differ significantly between the two groups (p>0.05). Concentrations of C-reactive protein, aspartate aminotransferase, alanine aminotransferase, and bilirubin were significantly higher in group B (p<0.005). Coronary arterial lesions (CAL) were found in 51 patients (23.2%) in group A and in 26 patients (48.1%) in group B during the acute stage, and in 14 patients (6.4%) in group A and in 11 patients (20.4%) in group B during the convalescent stage (p<0.005, respectively). A giant aneurysm was found in one patient in each group (0.5% in group A and 1.9% in group B; p<0.005) during the follow-up period.
CONCLUSION
A single infusion of medium-dose immunoglobulin was effective in 80% of patients with KD. About 20% of patients required two or more infusions of medium-dose immunoglobulin, who had higher concentrations of C-reactive protein, aspartate aminotransferase, alanine aminotransferase and bilirubin. The authors think that the medium-dose regimen proffers an advantage over the high-dose regimen in view of cost-effectiveness.

Keyword

Kawasaki disease; Immunoglobulin; Intravenous infusions

MeSH Terms

Alanine Transaminase
Aneurysm
Aspartate Aminotransferases
Bilirubin
C-Reactive Protein
Fever
Follow-Up Studies
Hemoglobins
Hospitals, General
Humans
Imidazoles
Immunoglobulins
Infusions, Intravenous
Leukocytes
Mucocutaneous Lymph Node Syndrome
Nitro Compounds
Platelet Count
Retrospective Studies
Alanine Transaminase
Aspartate Aminotransferases
Bilirubin
C-Reactive Protein
Hemoglobins
Imidazoles
Immunoglobulins
Nitro Compounds

Reference

1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004. 114:1708–1733.

2. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr. 1991. 119:279–282.

3. Engle MA, Fatica NS, Bussel JB, O'Loughlin JE, Snyder MS, Lesser ML. Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease: preliminary report. Am J Dis Child. 1989. 143:1300–1304.

4. Furusho K, Kamiya T, Nakano H, et al. Intravenous gammaglobulin for Kawasaki disease. Acta Paediatr Jpn. 1991. 33:799–804.

5. Barron KS, Murphy DJ, Silverman ED, et al. Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. J Pediatr. 1990. 117:638–644.

6. Ihn SM, Ann RZ, Kil HR, Chung YH. Selective gamma globulin treatment in Kawasaki disease: the comparison between single 1 g/kg and 2 g/kg. J Korean Pediatr Soc. 2000. 43:920–925.

7. Qin LJ, Wang HW, Hu XF, et al. Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study. Zhonghua Er Ke Za Zhi. 2006. 44:891–895.

8. Han SB, Choi JW, Kim SK, Chung SW, Kim JG, Son BK. The optimal dosages of gammaglobulin and aspirin in treating Kawasaki disease. J Korean Pediatr Soc. 1996. 39:703–711.

9. Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993. 87:1776–1780.

10. Choi CH, Byun SH, Jeon JD, Choi JW. Usefulness of echocardiographic findings in the early diagnosis of Kawasaki disease. Korean J Pediatr. 2007. 50:47–51.

11. Furusho K, Nakano H, Shinomiya K, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984. 2:1055–1058.

12. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991. 324:1633–1639.

13. Kang MK, Cho EY, Kim YH, et al. Treatment of Kawasaki disease with single high-dose intravenous gammaglobulin. J Korean Pediatr Soc. 1992. 35:342–348.

14. Moon SY, Kim NS, Lee HB, Lee H. Comparative study about the therapeutic effect between single and five-day administration of gammaglobulin in Kawasaki disease. Korean Circ J. 1994. 24:77–85.

15. Park YW, Han JW, Park IS, et al. Kawasaki disease in Korea, 2003-2005. Pediatr Infect Dis J. 2007. 26:821–823.

16. Research Committee on Kawasaki Disease. Reports of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. 1983. Tokyo: Ministry of Health and Welfare;48–54.

17. Nakano H, Ueda K, Saito A, Nojima K. Repeated quantitative angiograms in coronary arterial aneurysms in Kawasaki disease. Am J Cardiol. 1985. 56:846–851.

18. de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr. 1998. 133:254–258.

19. Takahashi M. Allen HD, Gutgesell HD, Clark EB, Driscoll DJ, editors. Kawasaki syndrome (mucocutaneous lymph node syndrome). Moss and Adams Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. 2000. 6th ed. Philadelphia: Lippincott Williams & Wilkins;1216–1225.